Ajanta Pharma Ltd
NSE:AJANTPHARM

Watchlist Manager
Ajanta Pharma Ltd Logo
Ajanta Pharma Ltd
NSE:AJANTPHARM
Watchlist
Price: 2 592.7 INR 4.45% Market Closed
Market Cap: 323.9B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AJANTPHARM stock under the Base Case scenario is 2 593.3 INR. Compared to the current market price of 2 592.7 INR, Ajanta Pharma Ltd is Fairly Valued.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AJANTPHARM Relative Value
Base Case
2 593.3 INR
Fairly Valued
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

7.1
P/S
P/S
Price to Sales
7.1
vs History
17
vs Industry
18
Median 3Y
5.9
Median 5Y
5.5
Industry
2.4
Forward
6.9
More Details
36.1
P/E
P/E
Price to Earnings
36.1
vs History
28
vs Industry
11
Median 3Y
34.3
Median 5Y
26.9
Industry
20.5
Forward
34.8
More Details
27.9
P/OCF
P/OCF
Price to OCF
27.9
vs History
71
vs Industry
14
Median 3Y
28.1
Median 5Y
28.1
Industry
15.6
More Details
35.9
P/FCFE
P/FCFE
Price to FCFE
35.9
vs History
84
vs Industry
13
Median 3Y
37.6
Median 5Y
43.5
Industry
23.1
More Details
8.8
P/B
P/B
Price to Book Value
8.8
vs History
15
vs Industry
6
Median 3Y
6.6
Median 5Y
5.5
Industry
2
More Details
7
EV/S
EV/S
Enterprise Value to Sales
7
vs History
19
vs Industry
18
Median 3Y
5.8
Median 5Y
5.3
Industry
2.5
Forward
6.7
More Details
9.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.1
vs History
25
vs Industry
22
Median 3Y
7.8
Median 5Y
7.2
Industry
4.9
More Details
25
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
25
vs History
23
vs Industry
14
Median 3Y
23.1
Median 5Y
18.8
Industry
12.3
Forward
24.1
More Details
28.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28.1
vs History
26
vs Industry
15
Median 3Y
26.4
Median 5Y
21.5
Industry
15.5
Forward
26.6
More Details
27.2
EV/OCF
EV/OCF
Enterprise Value to OCF
27.2
vs History
71
vs Industry
15
Median 3Y
27.5
Median 5Y
27.5
Industry
14.1
More Details
34.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
34.3
vs History
80
vs Industry
14
Median 3Y
35.9
Median 5Y
39.3
Industry
17.5
More Details
8.8
EV/IC
EV/IC
Enterprise Value to IC
8.8
vs History
15
vs Industry
9
Median 3Y
6.3
Median 5Y
5.4
Industry
1.8
More Details

Multiples Across Competitors

AJANTPHARM Competitors Multiples
Ajanta Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Ajanta Pharma Ltd
NSE:AJANTPHARM
323.9B INR 7.1 36.1 25 28.1
US
Eli Lilly and Co
NYSE:LLY
708.9B USD 14.5 64 34.3 37.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
359B USD 4 16.5 12 15.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.7 19.3 12.7 14.5
CH
Roche Holding AG
SIX:ROG
205.6B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
176.9B CHF 3.9 16.3 9.7 13
UK
AstraZeneca PLC
LSE:AZN
157.8B GBP 3.8 26.8 130.2 196.3
US
Merck & Co Inc
NYSE:MRK
195.9B USD 3.1 11.2 8.4 10.2
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130.2B USD 2.1 16.5 7.2 10.1
P/E Multiple
Earnings Growth PEG
IN
Ajanta Pharma Ltd
NSE:AJANTPHARM
Average P/E: 25.7
36.1
16%
2.3
US
Eli Lilly and Co
NYSE:LLY
64
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.5
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.3
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.3
17%
1
UK
AstraZeneca PLC
LSE:AZN
26.8
36%
0.7
US
Merck & Co Inc
NYSE:MRK
11.2
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Ajanta Pharma Ltd
NSE:AJANTPHARM
Average EV/EBITDA: 396.1
25
14%
1.8
US
Eli Lilly and Co
NYSE:LLY
34.3
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.7
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
130.2
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.4
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Ajanta Pharma Ltd
NSE:AJANTPHARM
Average EV/EBIT: 1 699.5
28.1
15%
1.9
US
Eli Lilly and Co
NYSE:LLY
37.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.8
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.3
21%
9.3
US
Merck & Co Inc
NYSE:MRK
10.2
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1

See Also

Summary
AJANTPHARM intrinsic value, competitors valuation, and company profile.
DCF Valuation
AJANTPHARM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AJANTPHARM stock valuation using valuation multiples.
Wall Street Estimates
AJANTPHARM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AJANTPHARM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.